Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/09/2019 09/10/2019 09/11/2019 09/12/2019 09/13/2019 Date
126.95(c) 129.55(c) 131.17(c) 130.43(c) 130.78(c) Last
7 684 665 8 239 733 6 203 628 5 250 032 5 369 774 Volume
-0.98% +2.05% +1.25% -0.56% +0.27% Change
More quotes
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 5 892 M
Yield 2019 2,87%
Sales 2020 85 081 M
EBIT 2020 27 980 M
Net income 2020 20 896 M
Finance 2020 1 151 M
Yield 2020 3,07%
P/E ratio 2019 19,5x
P/E ratio 2020 17,2x
EV / Sales2019 4,30x
EV / Sales2020 4,04x
Capitalization 345 B
More Financials
Company
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (49.9%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses,... 
Sector
Pharmaceuticals
Calendar
09/25Presentation
More about the company
Surperformance© ratings of Johnson & Johnson
Trading Rating : Investor Rating :
More Ratings
Latest news on JOHNSON & JOHNSON
09/13AMGEN : Phase 3 Study of Kyprolis, Darzalex Meets Primary Endpoint
DJ
09/13“THE DAY I MET SOME OF SAVE TH : How a Program in Bangladesh Is Helping Ne..
PU
09/12JOHNSON & JOHNSON : - New Head-to-Head Phase 3 Study Data Show Ponesimod Superio..
AQ
09/12JOHNSON & JOHNSON : The Janssen Pharmaceutical Companies - New Head-to-Head Phas..
AQ
09/10JOHNSON & JOHNSON : Janssen Pharmaceutical - New Data from Esketamine Nasal Spra..
AQ
09/10JOHNSON & JOHNSON : Janssen Pharmaceutical Companies - New Data from Esketamine ..
AQ
09/09JOHNSON & JOHNSON : J&J's Spravato Meets Primary Phase 3 Endpoints in Imminent S..
DJ
09/06JOHNSON & JOHNSON : Thinking about trading options or stock in Apple, Goldman Sa..
PR
09/05JOHNSON & JOHNSON : Announces Six Winners of the Champions of Science Africa Inn..
PU
09/05JOHNSON & JOHNSON : Announces Six Winners of the Champions of Science Africa Inn..
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Sector news : Pharmaceuticals - NEC
03:27aH LUNDBECK : Lundbeck buys Alder in $2 billion migraine treatment move
RE
02:48aA Plan to Fight Hep C -- WSJ
DJ
01:50aSANOFI : Abbott to Collaborate on Glucose Sensing, Insulin Delivery Data
DJ
09/14NOVARTIS : Trial and Error -2-
DJ
09/14NOVARTIS : Trial and Error
DJ
More sector news : Pharmaceuticals - NEC
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 148,50  $
Last Close Price 130,78  $
Spread / Highest target 29,2%
Spread / Average Target 13,5%
Spread / Lowest Target -5,18%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.34%345 150
ROCHE HOLDING LTD.12.28%236 116
MERCK AND COMPANY8.11%211 513
PFIZER-15.44%204 151
NOVARTIS16.65%200 777
NOVO NORDISK AS13.01%118 168